Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
01/2009
01/15/2009WO2009007751A2 Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
01/15/2009WO2009007750A1 Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k
01/15/2009WO2009007749A2 Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
01/15/2009WO2009007748A2 Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
01/15/2009WO2009007747A2 Hydantoin derivatives used as mmp12 inhibitors
01/15/2009WO2009007700A1 Treatment of melanoma
01/15/2009WO2009007697A1 New pharmaceutical formulation comprising cannabidiol and tetrahydrocannabidivarin
01/15/2009WO2009007696A1 Amino acid derivatives
01/15/2009WO2009007687A2 An inhalable medicament
01/15/2009WO2009007680A2 Combinations comprising a mast cell inhibitor and a statin for use in the treatment of inflammatory disorders
01/15/2009WO2009007679A2 Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a thromboxane a2 antagonist
01/15/2009WO2009007677A2 Dsb repair- inhibitors as anti-tumour agents
01/15/2009WO2009007675A2 Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a p2 gamma 12 antagonist
01/15/2009WO2009007674A2 Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and ramatroban or seratrodast
01/15/2009WO2009007673A2 Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a ppar gamma agonist
01/15/2009WO2009007660A1 Liquid or paste compositions intended to provide elements essential for the synthesis and formation of proteoglycans, in particular, for the treatment of cartilage degradation
01/15/2009WO2009007635A1 Chitosan carboxyalkylamide hydrogel, preparation thereof and cosmetic and dermatological use thereof
01/15/2009WO2009007622A2 Dermatological composition containing calcitriol lipidic vesicles, method for preparing same and use thereof
01/15/2009WO2009007457A2 Compounds and methods for modulating rho gtpases
01/15/2009WO2009007454A2 8-beta-substituted estratrienes as selectively active estrogens
01/15/2009WO2009007441A2 Crystalline form of (e) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile
01/15/2009WO2009007426A1 Oral pharmaceutical solutions containing telbivudine
01/15/2009WO2009007422A1 Thienopyrimidylamines as modulators of the ep2 receptor
01/15/2009WO2009007421A1 Indolylalkylthienopyrimidylamines as modulators of the ep2 receptor
01/15/2009WO2009007420A1 Novel bronchodilating alpha, beta-unsaturated isoquinoline amides
01/15/2009WO2009007419A1 Novel bronchodilating isoquinoline carbamates
01/15/2009WO2009007418A1 Novel bronchodilating isoquinoline amides
01/15/2009WO2009007415A2 Novel compounds
01/15/2009WO2009007412A2 Age deglycation
01/15/2009WO2009007411A2 Inhibition of age formation
01/15/2009WO2009007409A2 Oil in water emulsion comprising nsaids and quaternary ammonium halides
01/15/2009WO2009007399A1 New compounds as hsp90 inhibitors
01/15/2009WO2009007396A1 Nonsteroidal progesterone receptor modulators
01/15/2009WO2009007390A2 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors
01/15/2009WO2009007389A1 Stable pharmaceutical composition of a water-soluble vinorelbine salt
01/15/2009WO2009007388A1 Stable pharmaceutical composition comprising a hydrosoluble vinflunine salt
01/15/2009WO2009007376A1 Pharmaceutical compositions for peroral administration of phenothiazine dyestuffs
01/15/2009WO2009007348A2 Use of antagonists of g protein coupled receptors (gpcrs) for treating diseases caused by agonistic autoantibodies activated gpcrs
01/15/2009WO2009007334A2 Transdermal therapeutic systems which contain the substance anastrozole
01/15/2009WO2009007230A1 Use of nitric oxide releasing compounds in the treatment of chronic pain
01/15/2009WO2009007224A1 Low molecular weight heparin derivatives having neuroprotective activity
01/15/2009WO2009007187A1 Substituted 5-hetarylpyrimidines
01/15/2009WO2009007137A2 Pharmaceutical composition for topical application of poorly soluble compounds
01/15/2009WO2009007110A2 Combination of benzyl-4,5-dihydro-1h-imidazole derivative and an opiod recptor ligand
01/15/2009WO2009007080A1 Method of preventing and treating acute brain pathologies
01/15/2009WO2009007029A1 Imidazo-, pyrazolopyrazines and imidazotriazines and their use
01/15/2009WO2009007028A1 Prodrug derivatives of 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c]pyridine-3-carboxamide
01/15/2009WO2009007027A1 Aminoacyl prodrugs as an active pharmaceutical ingredient for thromboembolic disorders
01/15/2009WO2009007026A1 Aminoacyl prodrugs
01/15/2009WO2009007015A1 Malonamide derivatives with antithrombotic activity
01/15/2009WO2009006899A1 Compressed chewing gum tablet comprising taste-masking agent
01/15/2009WO2009006898A1 Stable medicated chewing gum comprising cyclodextrin inclusion complex
01/15/2009WO2009006839A1 Substituted indol-3-yl oxalylpodophyllotoxin derivates, their salts, and application thereof
01/15/2009WO2009006799A1 A pharmaceutical compositon comprising taxanes, the preparation and use thereof
01/15/2009WO2009006787A1 Composition comprising rotigotine, its use and transdermal patch comprising the composition
01/15/2009WO2009006773A1 AN OPTICALLY ACTIVE N- (α-MERCAPTOPROPIONY) GLYCINE
01/15/2009WO2009006699A1 Biofilm treatment
01/15/2009WO2009006686A1 Synergistic mixture
01/15/2009WO2009006668A1 Modulators of antigen-dependent t cell proliferation
01/15/2009WO2008147483A8 Neurogenic compounds
01/15/2009WO2008147480A8 Hydroxamic acid derivatives of 3-phenyl propionic acids useful as thrapeutic agents for treating anthrax poisoning
01/15/2009WO2008147445A3 Use of 5,6-dimethylxanthenone-4-acetic acid as an antimicrobial agent
01/15/2009WO2008144222A3 Triazolyl aminopyrimidine compounds
01/15/2009WO2008143706A3 Daa peripheral benzodiazepine receptor ligand for cancer imaging and treatment
01/15/2009WO2008143637A3 Compositions and methods for making therapies delivered by viral vectors reversible for safety or allele-specificity
01/15/2009WO2008142140A3 Novel 2,3-diamino-quinazolinone derivatives and their medical use
01/15/2009WO2008140574A3 Radiation protection and treatment for exposure to gamma-radiation
01/15/2009WO2008136865A9 (s)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
01/15/2009WO2008135661A3 Use of citrulline for the treatment of conditions linked to an increase in protein carbonylation
01/15/2009WO2008133952A3 Transmucosal treatment with fentanyl in patients with mucositis
01/15/2009WO2008132552A3 Omega-3 lipid compounds
01/15/2009WO2008132142A3 New heterocyclic derivatives useful for the treatment of cns disorders
01/15/2009WO2008131267A3 Low calcemic, highly antiproliferative, analogs of calcitriol
01/15/2009WO2008128191A3 Oral cephalotaxine dosage forms
01/15/2009WO2008124836A3 Methods of reducing virulence in bacteria
01/15/2009WO2008124083A3 Aurora kinase modulators and method of use
01/15/2009WO2008121352A3 Crystal forms of (r) -n-methylnaltrexone bromide and uses thereof
01/15/2009WO2008119810A3 Processes for the preparation of statins, particularly rosuvastatin, and intermediates for the preparation thereof
01/15/2009WO2008119790A3 Use of fluoride-containing compounds for diagnostic purposes with the help of imaging processes
01/15/2009WO2008115805A3 Cobalamin taxane bioconjugates
01/15/2009WO2008113686A3 Photoreactive ru (ii) complexes anchored on oligonucleotides, method for obtaining them and use thereof
01/15/2009WO2008112483A3 Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof
01/15/2009WO2008110699A3 Azabicycloalkane derivatives, preparation thereof and use thereof in therapy
01/15/2009WO2008109735A3 O6-alkylguanine-dna alkyltransferase inactivators
01/15/2009WO2008109544A9 Nucleic acid compounds for inhibiting muc1 gene expression and uses thereof
01/15/2009WO2008109532A4 Nucleic acid compounds for inhibiting fas gene expression and uses thereof
01/15/2009WO2008109373A9 Nucleic acid compounds for inhibiting erbb gene expression and uses thereof
01/15/2009WO2008107149A3 Pharmaceutical form with impeded abuse
01/15/2009WO2008102136A3 Solid pharmaceutical and vaccine dose
01/15/2009WO2008101914A3 N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
01/15/2009WO2008099198A3 Osteogenic compounds
01/15/2009WO2008097546A3 Compounds that inhibit cholinesterase
01/15/2009WO2008095912A3 Enantiopure pharmacologically active tricyclic benzimidazoles
01/15/2009WO2008089005A3 Renin inhibitors
01/15/2009WO2008085214A3 Treatment of esophageal high grade dysplasia using photodynamic therapy
01/15/2009WO2008079836A3 Macrocyclic factor viia inhibitors useful as anticoagulants
01/15/2009WO2008077170A3 Benzothioamides, and use thereof for relaxing smooth muscles
01/15/2009WO2008076247A3 Nitroderivatives as angiotensin ii receptor antagonists
01/15/2009WO2008076246A3 Nitroderivatives as angiotensin ii receptor antagonists
01/15/2009WO2008068656A3 Dermatological compositions